EA200501129A1 - Парентеральные композиции пептида для лечения системной красной волчанки - Google Patents

Парентеральные композиции пептида для лечения системной красной волчанки

Info

Publication number
EA200501129A1
EA200501129A1 EA200501129A EA200501129A EA200501129A1 EA 200501129 A1 EA200501129 A1 EA 200501129A1 EA 200501129 A EA200501129 A EA 200501129A EA 200501129 A EA200501129 A EA 200501129A EA 200501129 A1 EA200501129 A1 EA 200501129A1
Authority
EA
Eurasian Patent Office
Prior art keywords
peptide
composition
lork
treatment
humans
Prior art date
Application number
EA200501129A
Other languages
English (en)
Other versions
EA008438B1 (ru
Inventor
Шарон Кохен-Веред
Эсмира Нафтали
Вера Вайнштейн
Адриан Гилберт
Эти Клингер
Original Assignee
Тева Фармасьютикал Индастриз, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриз, Лтд. filed Critical Тева Фармасьютикал Индастриз, Лтд.
Publication of EA200501129A1 publication Critical patent/EA200501129A1/ru
Publication of EA008438B1 publication Critical patent/EA008438B1/ru

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Abstract

Настоящее изобретение относится к фармацевтической композиции, содержащей водный носитель, от 0,1 до 20 мг/мл композиции фармацевтически приемлемой соли пептида, имеющего структурную формулу NH-Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-COOH, и замещенный β-циклодекстрин в количестве, эффективном для растворения пептида в водном носителе, при этом композиция имеет pH от 4 до 9, к способу получения и способу ослабления симптомов системной красной волчанки (СКВ) у человека, включающему в себя введение человеку фармацевтической композиции.Отчет о международном поиске был опубликован 2005.03.24.
EA200501129A 2003-01-14 2004-01-14 Парентеральные композиции пептида для лечения системной красной волчанки EA008438B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43995003P 2003-01-14 2003-01-14
PCT/US2004/000955 WO2004064788A2 (en) 2003-01-14 2004-01-14 Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus

Publications (2)

Publication Number Publication Date
EA200501129A1 true EA200501129A1 (ru) 2006-02-24
EA008438B1 EA008438B1 (ru) 2007-06-29

Family

ID=32771763

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501129A EA008438B1 (ru) 2003-01-14 2004-01-14 Парентеральные композиции пептида для лечения системной красной волчанки

Country Status (18)

Country Link
US (2) US7294687B2 (ru)
EP (1) EP1587525A4 (ru)
JP (1) JP2006516034A (ru)
KR (1) KR20050100616A (ru)
CN (1) CN1761477A (ru)
AU (1) AU2004206844A1 (ru)
BR (1) BRPI0406737A (ru)
CA (1) CA2513331A1 (ru)
CO (1) CO5640149A2 (ru)
CR (1) CR7936A (ru)
EA (1) EA008438B1 (ru)
EC (1) ECSP055960A (ru)
MX (1) MXPA05007552A (ru)
NO (1) NO20053761L (ru)
NZ (1) NZ541659A (ru)
UA (1) UA83816C2 (ru)
WO (1) WO2004064788A2 (ru)
ZA (1) ZA200506205B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
CN1761477A (zh) * 2003-01-14 2006-04-19 特瓦制药工业有限公司 治疗***性红斑狼疮的肽的胃肠道外制剂
DK1594434T3 (da) * 2003-01-14 2017-01-02 Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science Parenterale formuleringer af peptide til behandling af systemisk lupus erythematosus
DE102004043750A1 (de) * 2004-09-10 2006-03-30 Sanofi-Aventis Deutschland Gmbh Formulierungen des Peptids p277 oder dessen Varianten mit optimierter Stabilität
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
US20100168011A1 (en) * 2006-12-12 2010-07-01 Amylin Pharmaceuticals, Inc. Pharmaceutical Formulations and Methods for Making the Same
CN101668561A (zh) * 2007-01-16 2010-03-10 彼帕科学公司 癌症治疗制剂
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
DK2814849T3 (da) 2012-02-15 2020-03-09 Cydex Pharmaceuticals Inc Fremgangsmåde til fremstilling af cyclodextrin-derivater
WO2014066274A1 (en) 2012-10-22 2014-05-01 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
JP6914188B2 (ja) 2014-08-22 2021-08-04 サイデックス・ファーマシューティカルズ・インコーポレイテッド 分画アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
AU2018205885A1 (en) 2017-01-05 2019-06-27 Yeda Research And Development Co. Ltd. Peptides for treating Sjogren's syndrome
CN110960442B (zh) * 2019-12-17 2023-03-31 珠海冀百康生物科技有限公司 一种多肽包封物的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60184098A (ja) 1984-03-02 1985-09-19 Suntory Ltd 新規なペプチド及びこれを有効成分とする利尿剤
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5126249A (en) 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9017008D0 (en) 1990-08-02 1990-09-19 Erba Carlo Spa Process for the enzymatic preparation of basic fibroblast growth factor
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
IL113159A0 (en) * 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
US6613536B1 (en) 1995-03-28 2003-09-02 Yeda Research And Development Co. Ltd. Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
IL120503A0 (en) 1997-03-20 1997-07-13 Hadasit Med Res Service Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them
US20020054872A1 (en) 1997-03-20 2002-05-09 Yaakov Naparstek Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus
DE69839221T2 (de) 1997-12-18 2009-04-30 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Pyridone als hemmer der sh2-domäne der src-familie
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US7114005B2 (en) 2002-02-05 2006-09-26 Cisco Technology, Inc. Address hopping of packet-based communications
DK1594434T3 (da) * 2003-01-14 2017-01-02 Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science Parenterale formuleringer af peptide til behandling af systemisk lupus erythematosus
CN1761477A (zh) * 2003-01-14 2006-04-19 特瓦制药工业有限公司 治疗***性红斑狼疮的肽的胃肠道外制剂

Also Published As

Publication number Publication date
ECSP055960A (es) 2006-04-19
CA2513331A1 (en) 2004-08-05
UA83816C2 (ru) 2008-08-26
CN1761477A (zh) 2006-04-19
NO20053761D0 (no) 2005-08-08
CO5640149A2 (es) 2006-05-31
US7294687B2 (en) 2007-11-13
ZA200506205B (en) 2006-12-27
WO2004064788A2 (en) 2004-08-05
EP1587525A4 (en) 2008-09-10
MXPA05007552A (es) 2006-05-19
CR7936A (es) 2006-05-31
BRPI0406737A (pt) 2005-12-20
US20080287366A1 (en) 2008-11-20
KR20050100616A (ko) 2005-10-19
WO2004064788A3 (en) 2005-03-24
EP1587525A2 (en) 2005-10-26
AU2004206844A1 (en) 2004-08-05
NO20053761L (no) 2005-10-12
EA008438B1 (ru) 2007-06-29
NZ541659A (en) 2007-05-31
US20040180059A1 (en) 2004-09-16
JP2006516034A (ja) 2006-06-15

Similar Documents

Publication Publication Date Title
CR7938A (es) Formulaciones parenterales de peptidos para el tratamiento de lupus eritematoso sistemico
NO20053761L (no) Parenterale peptidformuleringer for behandling av systemisk lupus erythematosus.
EA200000331A1 (ru) Фармацевтические композиции, содержащие белок плазмы
KR102645633B1 (ko) 신경학적 장애를 치료하는 방법
EA199900979A1 (ru) Композиции активированного протеина
KR880011199A (ko) 신규 펩타이드 화합물, 그의 제조방법 및 그를 함유하는 약학적 조성물
ATE254630T1 (de) Cyclosporine
EA200100972A1 (ru) Новые соединения и композиции как ингибиторы протеаз
EA200300942A1 (ru) Производные n-(арилсульфонил)бета-аминокислот, содержащие замещенную аминометильную группу, способ их получения и содержащие их фармацевтические композиции
MY129234A (en) Oral pharmaceutical forms of administration with a delayed action with tramadol.
ATE422356T1 (de) Pharmazeutische zubereitungen
KR20120060203A (ko) 신규한 오피오이드의 카바메이트 아미노산과 펩티드 프로드럭 및 그의 용도
WO2001012233A3 (en) Sustained release formulation of a peptide
JPS6021570B2 (ja) ド−パ類の高濃度製剤の製法
JP2016521249A (ja) リナクロチド組成物
EP3054969B1 (en) Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
EP0815870A2 (en) Composition for prohylaxis or treatment of cerebral infarction
JP2003504395A5 (ru)
EA200201232A1 (ru) Производные сульфонамида
EA200201234A1 (ru) Производные сульфонамида
KR890009974A (ko) 신규 화합물들
TW200509941A (en) Pharmaceutical solution composition
US20160367622A1 (en) Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
EA200400864A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ 2-(4-ЭТОКСИФЕНИЛ)-3-(4-МЕТАНСУЛЬФОНИЛФЕНИЛ)ПИРАЗОЛО[1,5-b]ПИРИДАЗИН В ФОРМЕ НАНОЧАСТИЦ
EP1348444A3 (en) Sustained release formulation of a peptide complexed with a polymer

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU